news
Immunotherapy treatment enhances lymphoma survival, landmark study shows
The Phase III findings give evidence for the immunotherapy treatment regimen to become standard of care for advanced Hodgkin lymphoma.
List view / Grid view
Hodgkin lymphoma
article
Leveraging innate cell engagers for lymphoma treatment
In this interview, Andreas Harstrick, CMO of Affimed discusses the evolution of the lymphoma treatment landscape and the promise of innate cell engagers for treating cancer.
news
Nivolumab plus chemo provides one-year PFS in 94 percent lymphoma patients
A PD-1 checkpoint inhibitor plus chemotherapy is expected to become new standard of care for advanced Hodgkin lymphoma, based on Phase III trial data.
article
Accelerating drug development
Here, Dave Elder explores how a ‘quick-approval, quick-withdrawal from the market’ approach is used to accelerate drug development.
article
Engaging the innate immune system to fight cancer effectively
Most therapeutic approaches in immuno-oncology focus on targeting the adaptive immune system; innate immunity has only recently gathered momentum. One of the most potent receptors for activating innate immune cells such as natural killer cells and macrophages is CD16A. Addressing this target mimics the body’s natural defense against potential threats,…
news
FDA expands approval of Adcetris for Stage III or IV classical Hodgkin lymphoma
The FDA has approved Adcetris to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy...
news
Scientists find genetic link between immune system and lymphoma
People who inherit genetic changes that alter the function of their immune system are at increased risk of developing Hodgkin lymphoma, according to new study by Institute of Cancer Research.
news
NICE asks BMS for more data before approving cancer drug
24 March 2017 | By Niamh Marriott, Junior Editor
NICE has asked Bristol Myers Squibb, who manufacture nivolumab (Opdivo), to provide more information on its effectiveness for treating Hodgkin lymphoma...
news
Five-year data from Phase II trial of Adcetris published
19 July 2016 | By Victoria White, Digital Content Producer
The data comes from a Phase II trial of Adcetris (brentuximab vedotin) in patients with relapsed or refractory classical Hodgkin lymphoma...
news
First-in-human trial of MundiPharma’s EDO-S101 starts
14 July 2016 | By Victoria White, Digital Content Producer
A first in class, fusion molecule, S101 is currently being developed for the treatment of relapsed-refractory haematological malignances...
news
EC extends conditional marketing authorisation for Adcetris
6 July 2016 | By Victoria White, Digital Content Producer
The EC has extended the current conditional marketing authorisation of Adcetris as consodlidation treatment in post-transplant Hodgkin lymphoma...
news
Positive CHMP opinion for Adcetris in post-transplant Hodgkin lymphoma
27 May 2016 | By Victoria White, Digital Content Producer
The opinion is for Adcetris for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following ASCT...
news
FDA accepts sBLA for Opdivo in classical Hodgkin Lymphoma
15 April 2016 | By Victoria White, Digital Content Producer
The FDA has accepted a sBLA for Opdivo that seeks to expand the use of the therapy to patients with Hodgkin Lymphoma after prior therapies...
news
Keytruda and AFM13 to be investigated in Hodgkin lymphoma
25 January 2016 | By Victoria White
The purpose of the study is to establish a dosing regimen for this combination therapy and assess its safety and efficacy...
news
Hodgkin’s lymphoma treatment market to hit $1.4b by 2024, says GlobalData
19 January 2016 | By Victoria White
GlobalData says the impressive growth in the market will be attributable to label extensions for Seattle Genetics’ Adcetris and the launch of new therapies for relapse or refractory Hodgkin’s lymphoma...
